Physician profile
Ali Azadi
NPI 1881810224
$8,337.06
in general payments reported to CMS, 2019-2025
28 companies · $2,254 in 2025
The $2,254 reported for 2025 was more than what 85% of Urogynecology and Reconstructive Pelvic Surgery (Obstetrics & Gynecology) providers received nationally (typical 2025 total: $413).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $864 · 2020: $388 · 2021: $912 · 2022: $1,391 · 2023: $879 · 2024: $1,648 · 2025: $2,254.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,377 · Travel and Lodging: $226 · Gift: $178.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,376.64 |
| Travel and Lodging | $225.98 |
| Gift | $177.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,741.67 | 2021-2025 | Interstim, Altaviva |
| Boston Scientific Corporation | $1,407.20 | 2019-2025 | Advantage System, Solyx Sis System, Axonics |
| Intuitive Surgical, INC. | $1,078.86 | 2019-2025 | Da Vinci Surgical System |
| Axonics, INC. | $578.07 | 2020-2024 | Bulkamid, Axonics |
| Coloplast Corp | $472.37 | 2019-2025 | |
| Astellas Pharma US INC | $472.27 | 2019-2025 | Veozah, Myrbetriq |
| Caldera Medical, INC | $425.38 | 2020-2023 | Desara |
| Abbvie INC. | $384.14 | 2019-2025 | Botox |
| Medtronic USA, INC. | $258.98 | 2019-2020 | |
| Hologic Sales and Service, LLC | $221.79 | 2022-2025 | Aptima, Myosure Tissue Removal Device, Omni Hysteroscope |
| Femselect INC. | $188.68 | 2024-2025 | Enplace |
| Sumitomo Pharma America, INC. | $168.23 | 2023-2025 | Myfembree, Gemtesa |
| Applied Medical Resources Corporation | $149.26 | 2022 | |
| Davol INC. | $131.90 | 2025 | Arista |
| E.R. Squibb & Sons, L.L.C. | $123.26 | 2025 | Camzyos |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $120.76 | 2021-2024 | Perclot, Floseal |
| Coopersurgical, INC. | $116.66 | 2019-2022 | |
| Allergan, INC. | $89.14 | 2019-2021 | |
| Therapeuticsmd, INC. | $46.23 | 2019 | |
| Channel Medsystems, INC. | $33.04 | 2022 | |
| Ethicon US, LLC | $30.37 | 2024 | Enseal X1 |
| Dilon Technologies, INC. | $25.53 | 2024 | Hemoblast Bellows |
| Glaxosmithkline, LLC. | $18.57 | 2025 | Benlysta |
| Minerva Surgical, INC | $15.57 | 2024 | |
| Abbott Laboratories | $14.99 | 2021 | |
| Myovant Sciences INC. | $12.14 | 2021 | |
| Covidien LP | $12.00 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Azadi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.